참고문헌
- Belanger MM, Gaudreau M, Roussel E, Couet J. Role of caveolin-1 in etoposide resistance development in A549 lung cancer cells. Cancer Biol Ther 3: 954-959, 2004 https://doi.org/10.4161/cbt.3.10.1112
- Bender FC, Reymond MA, Bron C, Quest AF. Caveolin-1 levels are down-regulated in human colon tumors, and ectopic expression of caveolin-1 in colon carcinoma cell lines reduces cell tumorigenicity. Cancer Res 60: 5870-5878, 2000
- Bruix J, Hessheimer A J, Forner A, Boix L, Vilana R, Llovet JM. New aspects of diagnosis and therapy of hepatocellular carcinoma. Oncogene 25: 3848-3856, 2006 https://doi.org/10.1038/sj.onc.1209548
- Cai C, Zhu H, Chen J. Overexpression of caveolin-1 increases plasma membrane fluidity and reduces P-glycoprotein function in Hs578T/Dox. Biochem Biophys Res Commun 320: 868-874, 2004 https://doi.org/10.1016/j.bbrc.2004.06.030
- Chen XP, Wang Q, Guan J, Huang ZY, Zhang WG, Zhang BX. Reversing multidrug resistance by RNA interference through the suppression of MDR1 gene in human hepatoma cells. World J Gastroenterol 12: 3332-3337, 2006 https://doi.org/10.3748/wjg.v12.i21.3332
- Davidson B, Goldberg I, Givant-Horwitz V, Nesland JM, Berner A, Bryne M, Risberg B, Kopolovic J, Kristensen GB, Trope CG, van de Putte G, Reich R. Caveolin-1 expression in ovarian carcinoma is MDR1 independent. Am J Clin Pathol 117: 225-234, 2002 https://doi.org/10.1309/U40R-1BN4-6KJ3-BDG3
- Dean M, Rzhetsky A, Allikmets R. The human ATP-binding cassette (ABC) t ransporter superfamily. Genome Res 11: 1156- 1166, 2001 https://doi.org/10.1101/gr.GR-1649R
- Demeule M, Jodoin J, Gingras D, Beliveau R. P-glycoprotein is localized in caveolae in resistant cells and in brain capillaries. FEBS Lett 466: 219-224, 2000 https://doi.org/10.1016/S0014-5793(00)01087-5
- Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 6: 674-687, 2006 https://doi.org/10.1038/nrc1934
- Fielding CJ, Fielding PE. Caveolae and intracellular trafficking of cholesterol. Adv Drug Deliv Rev 49: 251-264, 2001 https://doi.org/10.1016/S0169-409X(01)00140-5
- Galbiati F, Volonte D, Meani D, Milligan G, Lublin DM, Lisanti MP, Parenti M. The dually acylated NH2-terminal domain of gi1alpha is sufficient to target a green fluorescent protein reporter to caveolin-enriched plasma membrane domains. Palmitoylation of caveolin-1 is required for the recognition of dually acylated g-protein alpha subunits in vivo. J Biol Chem 274: 5843-5850, 1999 https://doi.org/10.1074/jbc.274.9.5843
- Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2: 48-58, 2002 https://doi.org/10.1038/nrc706
- Haber M, Burkhart CA, Regl DL, Madafiglio J, Norris MD, Horwitz SB. Altered expression of M beta 2, the class II beta-tubulin isotype, in a murine J774.2 cell line with a high level of taxol resistance. J Biol Chem 270: 31269-31275, 1995 https://doi.org/10.1074/jbc.270.52.31269
- Higgins CF. ABC transporters: from microorganisms to man. Annu Rev Cell Biol 8: 67-113, 1992 https://doi.org/10.1146/annurev.cb.08.110192.000435
- Kogo H, Fujimoto T. Caveolin-1 isoforms are encoded by distinct mRNAs. Identification of mouse caveolin-1 mRNA variants caused by alternative transcription initiation and splicing. FEBS Lett 465: 119-123, 2000 https://doi.org/10.1016/S0014-5793(99)01730-5
- Krajewska WM, Maslowska I. Caveolins: structure and function in signal transduction. Cell Mol Biol Lett 9: 195-220, 2004
- Lavie Y, Fiucci G, Liscovitch M. Up-regulation of caveolae and caveolar constituents in multidrug-resistant cancer cells. J Biol Chem 273: 32380-32383, 1998 https://doi.org/10.1074/jbc.273.49.32380
- Lavie Y, Fiucci G, Liscovitch M. Upregulation of caveolin in multidrug resistant cancer cells: functional implications. Adv Drug Deliv Rev 49: 317-323, 2001 https://doi.org/10.1016/S0169-409X(01)00144-2
- Li L, Ren CH, Tahir SA, Ren C, Thompson TC. Caveolin-1 maintains activated Akt in prostate cancer cells through scaffolding domain binding site interactions with and inhibition of serine/ threonine protein phosphatases PP1 and PP2A. Mol Cell Biol 23: 9389-9404, 2003 https://doi.org/10.1128/MCB.23.24.9389-9404.2003
- Li S, Okamoto T, Chun M, Sargiacomo M, Casanova JE, Hansen SH, Nishimoto I, Lisanti MP. Evidence for a regulated interaction between heterotrimeric G proteins and caveolin. J Biol Chem 270: 15693-15701, 1995 https://doi.org/10.1074/jbc.270.26.15693
- Li S, Song KS, Koh SS, Kikuchi A, Lisanti MP. Baculovirus-based expression of mammalian caveolin in Sf21 insect cells. A model system for the biochemical and morphological study of caveolae biogenesis. J Biol Chem 271: 28647-28654, 1996 https://doi.org/10.1074/jbc.271.45.28647
- Liscovitch M, Lavie Y. Multidrug resistance: a role for cholesterol efflux pathways- Trends Biochem Sci 25: 530-534, 2000 https://doi.org/10.1016/S0968-0004(00)01668-6
- Liu J, Oh P, Horner T, Rogers RA, Schnitzer JE. Organized endothelial cell surface signal transduction in caveolae distinct from glycosylphosphatidylinositol-anchored protein microdomains. J Biol Chem 272: 7211-7222, 1997 https://doi.org/10.1074/jbc.272.11.7211
- Liu P, Rudick M, Anderson RG. Multiple functions of caveolin-1. J Biol Chem 277: 41295-41298, 2002 https://doi.org/10.1074/jbc.R200020200
- Nerenstone SR, Ihde DC, Friedman MA. Clinical trials in primary hepatocellular carcinoma: current status and future directions. Cancer Treat Rev 15: 1-31, 1988 https://doi.org/10.1016/0305-7372(88)90066-7
- Nieth C, Priebsch A, Stege A, Lage H. Modulation of the classical multidrug resistance (MDR) phenotype by RNA interference (RNAi). FEBS Lett 545: 144-150, 2003 https://doi.org/10.1016/S0014-5793(03)00523-4
- Okamoto T, Schlegel A, Scherer PE, Lisanti MP. Caveolins, a family of scaffolding proteins for organizing 'preassembled signaling complexes' at the plasma membrane. J Biol Chem 273: 5419-5422, 1998 https://doi.org/10.1074/jbc.273.10.5419
- Pang A, Au WY, Kwong YL. Caveolin-1 gene is coordinately regulated with the multidrug resistance 1 gene in normal and leukemic bone marrow. Leuk Res 28: 973-977, 2004 https://doi.org/10.1016/j.leukres.2004.01.010
- Quest AF, Leyton L, Parraga M. Caveolins, caveolae, and lipid rafts in cellular transport, signaling, and disease. Biochem Cell Biol 82: 129-144, 2004 https://doi.org/10.1139/o03-071
- Razani B, Engelman JA, Wang XB, Schubert W, Zhang XL, Marks CB, Macaluso F, Russell R G., Li M, Pestell RG, Di Vizio D, Hou H Jr, Kneitz B, Lagaud G, Christ GJ, Edelmann W, Lisanti MP. Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. J Biol Chem 276: 38121-38138, 2001a
- Razani B, Zhang XL, Bitzer M, von Gersdorff G, Bottinger EP, Lisanti MP. Caveolin-1 regulates transforming growth factor (TGF)-beta/SMAD signaling through an interaction with the TGF-beta type I receptor. J Biol Chem 276: 6727-6738, 2001b https://doi.org/10.1074/jbc.M008340200
- Rosenbaum C, Rohrs S, Muller O, Waldmann H. Modulation of MRP-1-mediated multidrug resistance by indomethacin analogues. J Med Chem 48: 1179-1187, 2005 https://doi.org/10.1021/jm0499099
- Roy S, Luetterforst R, Harding A, Apolloni A, Etheridge M, Stang E, Rolls B, Hancock JF, Parton RG. Dominant-negative caveolin inhibits H-Ras function by disrupting cholesterol-rich plasma membrane domains. Nat Cell Biol 1: 98-105, 1999 https://doi.org/10.1038/10067
- Schlegel A, Schwab RB, Scherer PE, Lisanti MP. A role for the caveolin scaffolding domain in mediating the membrane attachment of caveolin-1. The caveolin scaffolding domain is both necessary and sufficient for membrane binding in vitro. J Biol Chem 274: 22660-22667, 1999a https://doi.org/10.1074/jbc.274.32.22660
- Schlegel A, Wang C, Katzenellenbogen BS, Pestell RG, Lisanti MP. Caveolin-1 potentiates estrogen receptor alpha (ERalpha) signaling. caveolin-1 drives ligand-independent nuclear translocation and activation of ERalpha. J Biol Chem 274: 33551-33556, 1999b https://doi.org/10.1074/jbc.274.47.33551
- Scotto KW, Johnson RA. Transcription of the multidrug resistance gene MDR1: a therapeutic target. Mol Interv 1: 117-125, 2001
- Shatz M, Liscovitch M. Caveolin-1 and cancer multidrug resistance: coordinate regulation of pro-survival proteins- Leuk Res 28: 907-908, 2004 https://doi.org/10.1016/j.leukres.2004.03.013
- Westermann M, Leutbecher H, Meyer HW. Membrane structure of caveolae and isolated caveolin-rich vesicles. Histochem Cell Biol 111: 71-81, 1999 https://doi.org/10.1007/s004180050335
- Williams TM, Lisanti MP. Caveolin-1 in oncogenic transformation, cancer, and metastasis. Am J Physiol Cell Physiol 288: C494-506, 2005 https://doi.org/10.1152/ajpcell.00458.2004
- Yang CP, Galbiati F, Volonte D, Horwitz SB, Lisanti MP. Upregulation of caveolin-1 and caveolae organelles in Taxol-resistant A549 cells. FEBS Lett 439: 368-372, 1998 https://doi.org/10.1016/S0014-5793(98)01354-4
- Zhu H, Cai C, Chen J. Suppression of P-glycoprotein gene expression in Hs578T/Dox by the overexpression of caveolin-1. FEBS Lett 576: 369-374, 2004 https://doi.org/10.1016/j.febslet.2004.09.041